|
Generic (Common) Name
|
Brand Name
|
Company
|
Year Approved
|
|
Protease Inhibitors (PIs)
|
|
amprenavir
|
Agenerase
|
GlaxoSmithKline
|
1999;
withdrawn 2007
|
|
atazanavir
|
Reyataz
|
Bristol-Myers Squibb
|
2003
|
|
darunavir (TMC114)
|
Prezista
|
Tibotec
|
2006
|
|
fosamprenavir
|
Lexiva (U.S.); Telzir (Europe)
|
GlaxoSmithKline
|
2003
|
|
indinavir
|
Crixivan
|
Merck
|
1996
|
|
lopinavir/ritonavir
|
Kaletra
|
Abbott
|
2000; Meltrex formulation 2005
|
|
nelfinavir
|
Viracept
|
Pfizer
|
1997
|
|
ritonavir
|
Norvir
|
Abbott
|
1996
|
|
saquinavir
|
Invirase (hard gel)
Fortovase (soft gel)
|
Roche
|
1995
1997; withdrawn 2005
|
|
tipranavir
|
Aptivus
|
Boehringer Ingelheim
|
2005
|
|
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
|
|
abacavir
|
Ziagen
|
GlaxoSmithKline
|
1998
|
|
didanosine (ddI)
|
Videx
|
Bristol-Myers Squibb
|
1989; Videx EC 2000
|
|
emtricitabine (FTC)
|
Emtriva
|
Gilead
|
2003
|
|
lamivudine (3TC)
|
Epivir
|
GlaxoSmithKline
|
1995
|
|
stavudine (d4T)
|
Zerit
|
Bristol-Myers Squibb
|
1994
|
|
tenofovir DF
|
Viread
|
Gilead
|
2002
|
|
zalcitabine (ddC)
|
Hivid
|
Roche
|
1992; withdrawn 2005
|
|
zidovudine (AZT)
|
Retrovir
|
GlaxoSmithKline
|
1987
|
|
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
|
|
delavirdine
|
Rescriptor
|
Pfizer
|
1997
|
|
efavirenz
|
Sustiva (U.S.); Stocrin (elsewhere)
|
Bristol-Myers Squibb
|
1998
|
|
Etravirine
|
Intelence
|
Tibotec
|
2008
|
|
nevirapine
|
Viramune
|
Boehringer Ingelheim
|
1996
|
|
Other Classes
|
|
enfuvirtide (T-20; fusion inhibitor)
|
Fuzeon
|
Trimeris
|
2003
|
|
maraviroc (CCR5 antagonist)
|
Selzentry (U.S.);
Celsentri (elsewhere)
|
Pfizer
|
2007
|
|
raltegravir (integrase inhibitor)
|
Isentress
|
Merck
|
2007
|
|
Fixed-Dose Combinations
|
|
lamivudine/abacavir (NRTI)
|
Epzicom (U.S.); Kivexa (Europe)
|
GlaxoSmithKline
|
2004
|
|
tenofovir/emtricitabine (NRTI)
|
Truvada
|
Gilead
|
2004
|
|
tenofovir/emtricitabine/
efavirenz (NRTI/NNRTI)
|
Atripla
|
Gilead/Bristol-Myers Squibb
|
2006
|
|
zidovudine/lamivudine (NRTI)
|
Combivir
|
GlaxoSmithKline
|
1997
|
|
zidovudine/lamivudine/abacavir (NRTI)
|
Trizivir
|
GlaxoSmithKline
|
2000
|
This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. Visit San Francisco AIDS Foundation's Web site to find out more about their activities, publications and services.
Email
Print-Friendly
Glossary
PDF
